MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.050
+0.210
+7.39%
After Hours: 3.050 0 0.00% 16:00 04/08 EDT
OPEN
2.860
PREV CLOSE
2.840
HIGH
3.070
LOW
2.800
VOLUME
413.79K
TURNOVER
--
52 WEEK HIGH
7.78
52 WEEK LOW
1.900
MARKET CAP
85.44M
P/E (TTM)
-0.8021
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADMS stock price target is 12.69 with a high estimate of 45.00 and a low estimate of 3.000.

EPS

ADMS News

More
  • Adamas Pharmaceuticals Stock Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.
  • GlobeNewswire · 03/23 20:15
  • Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
  • Zacks · 03/20 15:44
  • Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.
  • PR Newswire · 03/19 21:46
  • The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
  • Benzinga · 03/12 11:37

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About ADMS

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
More

Webull offers kinds of Adamas Pharmaceuticals Inc stock information, including NASDAQ:ADMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMS stock news, and many more online research tools to help you make informed decisions.